(RTTNews) - Biotechnology company Rocket Pharmaceuticals, Inc. (RCKT) announced Wednesday that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to RP-A501.
RP-A501 is the Company's investigational adeno-associated virus (AAV)-based gene therapy for the treatment of Danon Disease, a devastating and fatal inherited cardiomyopathy for which there are no curative therapies.
PRIME designation was granted based on positive safety and efficacy data from the Phase 1 clinical trial of RP-A501 in patients with Danon Disease and the potential of RP-A501 to meet the high unmet medical need in this population.
Results from the Phase 1 trial represent one of the most comprehensive investigational gene therapy datasets for any cardiac condition.
For More Such Health News, visit rttnews.com
ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xopZ6vo2TAtbvCpKpoqp%2BYuKbAjKmfmqqdlnq0rdisZJ6lkWK0s63NrapmqKKeuqZ5w56qop%2BelsGqu81mnaiqXae9bq2UaWhmn5Wjsm7Ax56pmqipYrOwvoydmKennmKxqr%2FEmqqeZWFlgHN%2FlWlta20%3D